400721-75-7

Basic information

• Product Name: Benzenemethanamine, 4-amino-2-chloro-
• CAS NO: 400721-75-7
• Molecular Formula: C7H9ClN2
• Molecular Weight: 156.615
• Mol File: 400721-75-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenemethanamine, 4-amino-2-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 4-amino-2-chloro-(400721-75-7)
• EPA Substance Registry System: Benzenemethanamine, 4-amino-2-chloro-(400721-75-7)

Safety Data

• Hazardous Substances Data: 400721-75-7(Hazardous Substances Data)

Upstream product

• 20925-27-3 4-amino-2-chlorobenzonitrile 

Downstream Products

• 1356124-82-7 N-[3-chloro-4-[[(2-chloroquinazolin-4-yl)amino]methyl]phenyl]-4-fluorobenzamide 
• 1356124-93-0 4-fluoro-N-[3-chloro-4-[[(2-(methylamino)quinazolin-4-yl)amino]methyl]phenyl]benzamide 
• 1356124-94-1 4-fluoro-N-[3-chloro-4-[[(2-(ethylamino)quinazolin-4-yl)amino]methyl]phenyl]benzamide 
• 1356124-78-1 C₁₄H₁₂ClFN₂O 
• 400720-72-1 tert-butyl (4-amino-2-chlorobenzyl)carbamate 

Relevant articles and documents

TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS

The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE

The present invention pertains to novel dual modulators of farnesoid X receptor (FXR) and soluble epoxide hydrolase (sEH). The modulators of the invention were designed to provide compounds which harbor a dual activity as agonists of FXR and inhibitors (antagonists) of sEH. The invention also provides methods for treating subjects suffering from diseases associated with FXR and sEH, such as metabolic disorders, in particular non-alcoholic fatty liver or nonalcoholic steatohepatitis (NASH).

Design, synthesis, and biological evaluation of new diaminoquinazolines as β-catenin/Tcf4 pathway inhibitors

More than 50 new diaminoquinazoline derivatives have been synthesized and evaluated in a colon carcinoma cell growth inhibition assay using HCT116 and SW480 cells. Twenty compounds with good cell growth inhibitory activities (50 values 50 values of 1.5-2.5 μM for HCT116 cells with the luciferase reporter assay.